For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
DelveInsight's, "Glioblastoma - Pipeline Insight, 2021," report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Glioblastoma Understanding
Glioblastoma: Overview
Glioblastoma, also known as Glioblastoma Multiforme, is a fast growing glioma that develops from star shaped glial cells (astrocytes) that supports the health of nerve cells in the brain. A grading system from I to IV defines the rate of tumor growth grade I indicating slow growth and grade IV indicating rapid growth. A risk factor known to be associated with glioblastoma is prior ionizing radiation therapy that uses high energy waves/particles to destroy cancer cells but can also cause normal cells to be damaged and even lead to new cancer cells forming. Other risk factors include exposure to vinyl chloride and pesticides. Suspected individuals with glioblastoma undergoes physical and neurological examination. Sophisticated imaging techniques can very accurately pinpoint the location of brain tumors. Diagnostic tools include computed tomography (CT or CAT scan) and magnetic resonance imaging (MRI). Treatment options for glioblastoma include a combination of surgery, radio therapy, chemotherapy, and alternating electric fields therapy. Temozolomide is a Food and Drug Administration (FDA) approved therapy for the treatment of glioblastoma.
"Glioblastoma - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Glioblastoma pipeline landscape is provided which includes the disease overview and Glioblastoma treatment guidelines. The assessment part of the report embraces, in depth Glioblastoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Glioblastoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Glioblastoma R&D. The therapies under development are focused on novel approaches to treat/improve Glioblastoma.
Glioblastoma Emerging Drugs Chapters
This segment of the Glioblastoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Glioblastoma Emerging Drugs
- ONC201: Oncoceutics
ONC201 is an orally administered small molecule dopamine receptor D2 (DRD2) antagonist and caseinolytic protease (ClpP) agonist. The FDA has granted ONC201 Fast Track Designation for the treatment of adult recurrent H3 K27M-mutant high-grade glioma, Rare Pediatric Disease Designation for treatment of H3 K27M-mutant glioma, and Orphan Drug Designations for the treatment of glioblastoma and for the treatment of malignant glioma. ONC201 is currently in a registrational clinical trial for recurrent H3 K27M-mutant glioma and a confirmatory response rate assessment is expected in 2021.
- VAL-083: Kintara Therapeutics
VAL-083 is a first-in-class small molecule bifunctional alkylating agent that has the ability to cross the blood-brain barrier. The drug is indicated for the treatment of chronic myeloid leukemia and lung cancer; and in Phase III clinical studies for the treatment of glioblastoma.
Further product details are provided in the report ..
Glioblastoma: Therapeutic Assessment
This segment of the report provides insights about the different Glioblastoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Glioblastoma
There are approx. 100+ key companies which are developing the therapies for Glioblastoma. The companies which have their Glioblastoma drug candidates in the most advanced stage, i.e. Phase III include, Kintara Therapeutics.
- Phases
DelveInsight's report covers around 100+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Glioblastoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Glioblastoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glioblastoma drugs.
Glioblastoma Report Insights
- Glioblastoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Glioblastoma Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Glioblastoma drugs?
- How many Glioblastoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Glioblastoma?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Glioblastoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Glioblastoma and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Celgene Corporation
- Myeloid Therapeutics
- Genenta Science
- Inovio Pharmaceuticals
- Apogenix
- Oncoceutics
- Laminar Pharmaceuticals
- Celgene Corporation
- Bristol-Myers Squibb
- Kintara Therapeutics
- Kazia Therapeutics
- Oncotelic Therapeutics
- AstraZeneca
- Genentech
- Accendatech
- Pfizer
- Curtana Pharmaceuticals
- Crimson BioPharm
- Hope Biosciences
Key Products
- Trotabresib
- MT 201
- Temeferon
- INO5401
- Asunercept
- ONC 201
- 2-Hydroxyoleic acid
- Marizomib
- Nivolumab
- VAL-083
- Paxalisib
- Trabedersen
- Olaparib
- Atezolizumab
- ACT-001
- Crizotinib
- CT 179
- CM 93
- HB-adMSC
?